Advances in mRNA non-viral delivery approaches.

Autor: Ibba ML; Department of Molecular Medicine and Medical Biotechnology, 'Federico II' University of Naples, 80131 Naples, Italy., Ciccone G; Institute Experimental Endocrinology and Oncology 'Gaetano Salvatore' (IEOS), National Research Council (CNR), 80145 Naples, Italy., Esposito CL; Institute Experimental Endocrinology and Oncology 'Gaetano Salvatore' (IEOS), National Research Council (CNR), 80145 Naples, Italy. Electronic address: c.esposito@ieos.cnr.it., Catuogno S; Institute Experimental Endocrinology and Oncology 'Gaetano Salvatore' (IEOS), National Research Council (CNR), 80145 Naples, Italy. Electronic address: s.catuogno@ieos.cnr.it., Giangrande PH; University of Iowa, Department of Internal Medicine, Iowa City, IA, USA; Wave Life Sciences, Cambridge, MA, USA. Electronic address: pgiangrande@wavelifesci.com.
Jazyk: angličtina
Zdroj: Advanced drug delivery reviews [Adv Drug Deliv Rev] 2021 Oct; Vol. 177, pp. 113930. Date of Electronic Publication: 2021 Aug 14.
DOI: 10.1016/j.addr.2021.113930
Abstrakt: Messenger RNAs (mRNAs) present a great potential as therapeutics for the treatment and prevention of a wide range of human pathologies, allowing for protein replacement, vaccination, cancer immunotherapy, and genomic engineering. Despite advances in the design of mRNA-based therapeutics, a key aspect for their widespread translation to clinic is the development of safe and effective delivery strategies. To this end, non-viral delivery systems including peptide-based complexes, lipidic or polymeric nanoparticles, and hybrid formulations are attracting growing interest. Despite displaying somewhat reduced efficacy compared to viral-based systems, non-viral carriers offer important advantages in terms of biosafety and versatility. In this review, we provide an overview of current mRNA therapeutic applications and discuss key biological barriers to delivery and recent advances in the development of non-viral systems. Challenges and future applications of this novel therapeutic modality are also discussed.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: